America's Best Nonprofits
  1. Home
  2. Disease & Disorders
  3. Glen Ridge, NJ
  4. Congenital Hyperinsulinism International

Congenital Hyperinsulinism International

Congenital Hyperinsulinism International is ranked among disease & disorders organizations in Glen Ridge, NJ, with an America's Best Score of 88 out of 100, based on its 2025 Form 990.

  • Glen Ridge, NJ
  • Tax-exempt since 2006
  • EIN: 20-3068945
congenitalhi.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
88OF 100 Ranked in Glen Ridge Disease & Disorders How this score is calculated

Organization summary

Congenital Hyperinsulinism International is a 501(c)(3) organization, classified under Disease & Disorders (NTEE G12). Contributions are tax-deductible.

Po Box 135, Glen Ridge, NJ 07028-0135

In fiscal year 2025 it reported $2,151,606 in revenue and $1,412,559 in expenses, with contributions making up 21.4% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

Congenital Hyperinsulinism International ("CHI") is a nonprofit 501(c)(3) corporation dedicated to improving the lives of babies, children, and adults affected by congenital hyperinsulinism (HI). HI is a life-threatening genetic disorder that causes severe low blood sugar (hypoglycemia) in infants and children, though in 50% of patients, the genetic cause is unknown. For those with HI, the beta cells of the pancreas secrete too much insulin in an unregulated manner. Excess insulin causes hypoglycemia. Prolonged or severe hypoglycemia can cause seizures, permanent brain damage, or even death if left untreated. Timely diagnosis and proper management are important for neurodevelopment.

Largest programs · fiscal year 2025

  • Research and Development-- CHI supports and conducts research to better understand, treat, manage, and hopefully cure HI. CHI shares the patient perspective with researchers and members of the biopharmaceutical industry to accelerate the development of patient-centered treatments, and provides patient-experience consulting to biotechnology companies and researchers developing investigational treat… Read more

    Research and Development-- CHI supports and conducts research to better understand, treat, manage, and hopefully cure HI. CHI shares the patient perspective with researchers and members of the biopharmaceutical industry to accelerate the development of patient-centered treatments, and provides patient-experience consulting to biotechnology companies and researchers developing investigational treatments for HI.CHI is a part of the Million Dollar Bike Ride grant program with the University of Pennsylvania's Center for Orphan Diseases; a pilot research grant is offered each year for an innovative, preclinical or clinical study with the potential to lead to a better HI treatment, a cure for HI, or improvement in the quality of life for those affected by HI. In 2025, CHI was able to award one pilot research grant through this program, supported in part by the annual Million Dollar Bike Ride fundraising event held in Philadelphia, PA. The period for this awarded grant begins on October 1,2026.CHI conducts the HI Global Registry (HIGR) research project, an online platform for the HI patient community to share their experiences of living with HI and their glucose monitoring values. With the patient families' permission, MaxHIGR provides complementary data from the physician's perspective. By participating in the HI Global Registry, the patient community helps themselves and researchers better understand HI to advance better treatments, a potential cure, and more timely and accurate diagnoses. A HIGR report is published each year by CHI staff, and scholars and researchers may request deidentified data for their research projects. In 2025, CHI launched a partnership with Dexcom to improve access to continuous glucose monitors (CGM) for members of the HI community in the United States.In 2025, CHI also continued or launched several additional research initiatives, including the HI Global Registry, the HI/HA Natural History Study, and a pancreatectomy research study, along with ongoing research resources maintained on CHI's website. In 2025, CHI research was also presented via posters at the following meetings: the Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) in Copenhagen, Denmark; the PES Annual Meeting in National Harbor, MD; the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, IL; the 2025 NORD Breakthrough Summit in Washington, DC; the Diabetes Technology Meeting hosted by the Diabetes Technology Society in Burlingame, CA; The Global Pediatric Endocrine and Diabetes Annual Meeting 2025 (virtual);and Hot Topics in Neonatology, hosted by Nemours Children's Health, in Washington, DC. CHI staff also attended and presented at the Chan Zuckerberg Initiative (CZI) Science in Society: Rare As One Network Meeting (Nevada), and the CZI Ciliopathies in Focus Workshop, Redwood City, CA.In 2025, CHI continued to lead the Collaborative Research Network (CRN), a project of CHI dedicated to the development of faster and more accurate diagnoses, new evidence-based treatments and cures, standardized clinical guidelines, and increased and improved access to treatment, medication, devices, and supplies. This ambitious project includes working groups focused on different aspects of a prioritized research agenda (PRA) developed by the CRN's members, which include 60 leading researchers, clinicians, and patient advocates from 17 countries. In 2025, the CRN held virtual meetings throughout the year as well as an in-person convening in Lisbon, Portugal (February 28March 2), and advanced small-group projects on Universal Newborn Screening, Continuous Glucose Monitoring for HI, and advocacy focused on access and on awareness reflecting the PRA's top priorities of Newborn Screening, Glucose as a Vital Sign, Care Guidelines, Natural History, and Continuous Glucose Monitoring. Since the CRN's launch in 2020, its members have published a total of 198 articles on congenital hyperinsulinism covering genetics, treatment, disease management, monitoring and technology, screening and diagnostics, clinical guidelines, education, patient experience, quality of life, policy, and access to care.In 2025, CHI staff and CHI Collaborative Research Network (CRN) members co-authored or contributed to several peer-reviewed publications, including:EndoCompass project: research roadmap for diabetes, obesity, and metabolism, adapted the results of the CRN's congenital hyperinsulinism prioritized research agenda for adoption by the European Society for Endocrinology and the European Society for Paediatric Endocrinology through the EndoCompass Research Roadmap.Global Disparities in Congenital Hyperinsulinism Care, highlighting limitations in care access worldwide and calling for collaborative research to promote equitable care;Real-world experience with the use of diazoxide among people living with congenital hyperinsulinism and their caregivers, drawing on HI Global Registry (HIGR) data and qualitative interviews to examine diazoxide use, side effects, and daily quality-of-life impact;Developing a congenital hyperinsulinism prioritized research agenda: a patient-driven international collaborative research network, published in Frontiers in Endocrinology, sharing the CRN's roadmap of research priorities to advance diagnosis, treatment, and cures for HI.Additionally, CHI staff and CHI Collaborative Research Network (CRN) members co-authored the following publication:Neonatal hypoglycaemia: consider hyperinsulinism, an overview for midwives, neonatal nurses, and other birthing professionals on the importance of severe hypoglycemia detection; andCHI continues to support the Open Hyperinsulinism Genes Program in partnership with the University of Exeter in the UK. This program is the first point-of-need international genetic testing service for HI and is also accelerating scientific knowledge through the creation of a self-sustaining research gene discovery pipeline. As of December 31, 2025, 1,176 samples from individuals affected by congenital hyperinsulinism and 871 samples from family members, from 65 countries on 5 continents, have been tested through this program.In 2025, CHI continued to support the CHI Centers of Excellence Designation. Currently, eight centers around the world have been granted the designation and are recognized as multi-disciplinary clinical and research centers in the field of congenital hyperinsulinism. The goals of this program are to make it easier for patient families to access care at leading hospitals, encourage patient-focused standards at the leading hospitals, foster a pipeline of expert clinicians and researchers, and encourage collaboration among researchers, clinicians, and patient leaders and advocates.In 2025, CHI continued its work as part of the international, 11-member LightCure Consortium, a project made possible by a grant from the European Union research arm Horizon Europe encompassing CHI's work to strengthen patient engagement and raise worldwide awareness of HI and its myriad challenges. The Consortium held an in-person meeting in Lisbon, Portugal, and in 2025 CHI released its documentary short film, Turn Hours into a Lifetime, which follows three hyperinsulinism families from around the world and highlights the importance of detecting and treating severe hypoglycemia early to prevent brain damage and death.

    $659,406 spent · 52.4% of program spending
  • Awareness and Education-- CHI increases public and medical personnel's awareness of HI to improve timely diagnosis and guideline-driven management, thereby reducing adverse neurological outcomes and deaths. To that end, CHI spreads awareness of HI with ongoing campaigns on social media, the CHI website and blog, CHI posters in 25 languages, Glucose as a Vital Sign, Global Hyperinsulinism Day, HI S… Read more

    Awareness and Education-- CHI increases public and medical personnel's awareness of HI to improve timely diagnosis and guideline-driven management, thereby reducing adverse neurological outcomes and deaths. To that end, CHI spreads awareness of HI with ongoing campaigns on social media, the CHI website and blog, CHI posters in 25 languages, Glucose as a Vital Sign, Global Hyperinsulinism Day, HI Simplified Postcards, brochures, the HI Sibling Book, and educational videos, as well as through direct mail, email, and at meetings and conferences.CHI provides educational resources and hosts conferences and meetings on HI for people with HI, their families, clinicians, researchers, and members of the biotech industry. To date, CHI has held 35 family and research meetings and conferences with presentations from academic researchers, members of advocacy organizations, HI patients and families, and biotechnology companies. In 2025, CHI's conference and outreach activities included hosting a virtual Rare Disease Day event; a CHI Family Conference in Copenhagen, Denmark; a CHI Family Conference co-hosted at Children's Hospital of Philadelphia; and exhibit booths at the European Society for Paediatric Endocrinology/European Society of Endocrinology (ESPE/ESE) joint meeting in Copenhagen, the Pediatric Endocrine Society (PES) annual meeting in the Washington, DC area, the American Diabetes Association (ADA) scientific sessions meeting in Chicago, the 2025 NORD Breakthrough Summit in Washington, DC, and Hot Topics in Neonatology in Washington, DC.

    $321,771 spent · 25.6% of program spending
  • Family and Patient Support--CHI advocates on behalf of HI families all over the world for access to quality treatment, medication, and supplies. In 2025, this included CHI's Direct Relief Partnership and its WEP Clinical Partnership, which support access to treatment, medication, and supplies for the HI community. CHI establishes benevolence funds at hospitals including Children's Hospital of Phil… Read more

    Family and Patient Support--CHI advocates on behalf of HI families all over the world for access to quality treatment, medication, and supplies. In 2025, this included CHI's Direct Relief Partnership and its WEP Clinical Partnership, which support access to treatment, medication, and supplies for the HI community. CHI establishes benevolence funds at hospitals including Children's Hospital of Philadelphia (PA), Cook Children's Medical Center (Fort Worth, TX), and Great Ormond Street Hospital (London, UK) to support families from out of town who must travel to centers of excellence for patient care. CHI provides opportunities for affected families to emotionally support each other, since the home care medical management of HI is often complicated and difficult. CHI offers online forums and a Facebook support page, has a volunteer CHI mentor program to connect families with HI parents located in different parts of the world, and makes CHI staff and volunteers available by telephone, and in person for support. CHI's programs are supported in part by fundraising events, including the Million Dollar Bike Ride in Philadelphia, PA and the Sugar Soire.

    $277,615 spent · 22.1% of program spending

Where each dollar went · fiscal year 2025

Of every dollar it spent, 89¢ went to programs, 4¢ to management and 7¢ to fundraising.

  • Programs $1,258,792
  • Management $59,869
  • Fundraising $93,898

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score88 / 100
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves22.0 mo; 18.8 mo in cash15.3 / 25
Financial balance (median margin)+32.3%19.8 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+19.2% / yr15 / 15
Track record20 years8 / 10
Debt load1.1% of assets10 / 10
Total88.1 → 88
Spending on programs
Not scored; America's Best needs 65%+
89%Meets

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$2,151,606Fiscal year 20252022: $1,262,62520222023: $1,150,29120232024: $1,275,77420242025: $2,151,6062025
Expenses$1,412,559Fiscal year 20252022: $834,05520222023: $1,043,44620232024: $1,126,85520242025: $1,412,5592025
Total assets$2,618,333Fiscal year 20252022: $1,644,31520222023: $1,803,32320232024: $2,173,95520242025: $2,618,3332025
Total liabilities$28,600Fiscal year 20252022: $46,62620222023: $98,78920232024: $320,50220242025: $28,6002025
Fiscal year ending December 2025
Revenue$2,151,606
Expenses$1,412,559
Net income$739,047
Net assets$2,589,733

Notable sources of revenue

Percent of total revenue
Contributions$461,275
Program services$1,663,929
Investment income$61,770
Other (net)−$35,368

Assets / debt

Total assets$2,618,333
Total liabilities$28,600
Net assets$2,589,733

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$1,275,774
Expenses$1,126,855
Net income$148,919
Net assets$1,853,453

Notable sources of revenue

Percent of total revenue
Contributions$260,171
Program services$978,110
Investment income$63,858
Other (net)−$26,365

Assets / debt

Total assets$2,173,955
Total liabilities$320,502
Net assets$1,853,453

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$1,150,291
Expenses$1,043,446
Net income$106,845
Net assets$1,704,534

Notable sources of revenue

Percent of total revenue
Contributions$463,103
Program services$694,586
Investment income$25,235
Other (net)−$32,633

Assets / debt

Total assets$1,803,323
Total liabilities$98,789
Net assets$1,704,534

Compensation

Not in our extract for this year.

Fiscal year ending December 2022
Revenue$1,262,625
Expenses$834,055
Net income$428,570
Net assets$1,597,689

Notable sources of revenue

Percent of total revenue
Contributions$477,854
Program services$812,623
Investment income$0
Other (net)−$27,852

Assets / debt

Total assets$1,644,315
Total liabilities$46,626
Net assets$1,597,689

Compensation

Officers and key employees$93,866
Share of expenses11.3%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?